Welcome to our dedicated page for Ascendis Pharma A/S SEC filings (Ticker: ASND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Ascendis Pharma A/S's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Ascendis Pharma A/S's regulatory disclosures and financial reporting.
Ascendis Pharma A/S executive Michael Wolff Jensen has filed a Form 3 detailing his equity-based holdings in the company. As EVP and Chief Legal Officer, he reports fully vested, currently exercisable warrants over 30,000 ordinary shares at an exercise price of 62.1700 per share, additional warrants over 27,000 shares at 108.0000, 22,755 shares at 176.2800, and 14,504 shares at 139.6500, all held directly.
He also reports restricted stock units representing 4,246, 3,197 and 9,552 ordinary shares. According to the footnotes, one RSU grant vests on March 1, 2027 with no expiration date, while other grants vest in two or three equal annual installments beginning on March 1, 2027. Each restricted stock unit corresponds to a contingent right to receive one ADS.
Ascendis Pharma A/S executive Mads Bodenhoff, SVP & PAO, reports existing equity-based holdings in the company. He holds warrants over 30,000, 3,117 and 3,687 underlying ordinary shares with exercise prices of 124.5200, 139.6500 and 110.0000, expiring between July 13, 2031 and October 11, 2032, with at least one warrant grant fully vested and currently exercisable.
He also holds restricted stock units covering 2,634, 3,967 and 2,768 underlying ordinary shares, each RSU representing a contingent right to receive one ADS. These RSUs vest on or beginning March 1, 2027, with some grants vesting in two or three equal annual installments and having no expiration date.
Ascendis Pharma A/S executive Anni Lotte Kirstine Sonderbjerg Pedersen has filed an initial Form 3 detailing her equity holdings. She directly owns 19,460 Ordinary Shares. In addition, she holds several series of fully vested, currently exercisable warrants over 20,000, 45,000, 27,000, 22,755 and 14,504 Ordinary Shares with exercise prices ranging from 37.1800 to 176.2800 and expirations between 2027 and 2031.
She also holds Restricted Stock Units over 4,246, 6,394 and 9,552 underlying Ordinary Shares. Footnotes state that certain RSUs vest on March 1, 2027, with others vesting in two or three equal annual installments beginning on that date, and each RSU represents a contingent right to receive one American Depositary Share, with each ADS representing one Ordinary Share. The filing reports holdings only, with no purchases or sales.
Ascendis Pharma A/S director Lisa Morrison filed an initial ownership report showing a mix of ordinary shares, warrants and restricted stock units tied to ordinary shares and American Depositary Shares. She holds 1,572 ordinary shares directly, fully vested warrants over multiple strike prices, and several RSU awards that begin vesting on March 1, 2027.
Ascendis Pharma A/S director Lars Holtug has filed an initial statement of beneficial ownership, detailing his equity interests in the company. He reports direct holdings of 4,236 Ordinary Shares, which may be held as American Depositary Shares where each ADS represents one Ordinary Share.
Holtug also holds warrants over 35,000, 7,500, 6,420 and 3,053 underlying Ordinary Shares at exercise prices of 61.0000, 108.0000, 176.2800 and 139.6500 respectively, expiring between November 13, 2028 and December 9, 2031. The warrants are fully vested and currently exercisable.
In addition, he holds restricted stock units covering 1,374, 2,070 and 1,930 underlying Ordinary Shares, each RSU representing a contingent right to receive one ADS. These RSUs vest beginning on March 1, 2027, with some vesting entirely on that date and others in two or three equal annual installments thereafter.
Ascendis Pharma A/S officer SPROGOE KENNETT filed an initial Form 3 showing existing equity holdings, rather than new transactions. The filing lists fully vested and currently exercisable warrants over 5,313, 45,000, 27,000, 22,755 and 14,504 Ordinary Shares at exercise prices of $37.18, $62.17, $108.00, $176.28 and $139.65 per share, respectively. It also reports three blocks of restricted stock units covering 4,246, 3,197 and 9,552 Ordinary Shares, which vest beginning on March 1, 2027 in one‑, two‑ and three‑year installment schedules and have no expiration date. In addition, the officer holds 19,460 Ordinary Shares directly and 110 Ordinary Shares indirectly through children. The footnotes clarify that each restricted stock unit corresponds to a right to receive one American Depositary Share, and each ADS represents one Ordinary Share.
Ascendis Pharma A/S executive Jay Donovan Wu filed an initial Form 3 reporting his equity holdings. He holds warrants covering 45,078 ordinary shares at an exercise price of 131.57 per share expiring on January 14, 2035, restricted stock units for 3,333 and 9,553 ordinary shares that vest in equal annual installments beginning on March 1, 2027, and 1,068 ordinary shares (including ADS) directly.
Ascendis Pharma A/S director Jan Moller Mikkelsen filed an initial ownership report showing a mix of ordinary shares, warrants and restricted stock units. He directly holds 384,933 ordinary shares and indirectly holds 68,470 ordinary shares through Cadenza Partners.
The filing lists several fully vested, currently exercisable warrant series over ordinary shares with exercise prices ranging from 37.18 to 176.28 and expirations from December 2027 through December 2031. It also discloses three restricted stock unit awards over ordinary shares (delivered as ADSs) covering 15,825, 23,834 and 28,945 underlying shares, which vest beginning on March 1, 2027.
Ascendis Pharma A/S officer Jensen Flemming Steen filed an initial ownership report showing a mix of ordinary shares, warrants, and restricted stock units tied to the company’s equity. He holds 19,460 ordinary shares directly, including American Depositary Shares where each ADS represents one ordinary share.
His derivative position includes fully vested, currently exercisable warrants over 20,000, 27,000, 22,755 and 14,504 ordinary shares at exercise prices of 62.1700, 108.0000, 176.2800 and 139.6500 respectively. He also holds restricted stock units covering 4,246, 3,197 and 9,552 ordinary shares, each RSU representing a contingent right to receive one ADS. These RSUs vest over time beginning on March 1, 2027 and have no expiration date.
Ascendis Pharma A/S director Cha Albert has filed an initial ownership report showing a mix of ordinary shares, warrants and restricted stock units. The filing lists 3,730 ordinary shares held directly. It also discloses fully vested warrants over 542 ordinary shares at an exercise price of $62.1700 expiring on December 11, 2028, 7,500 ordinary shares at $108.0000 expiring on December 10, 2029, 6,420 ordinary shares at $176.2800 expiring on December 10, 2030, and 3,053 ordinary shares at $139.6500 expiring on December 9, 2031. In addition, Cha holds restricted stock units covering 1,374, 2,070 and 1,930 ordinary shares, each representing a right to receive one American Depositary Share, with vesting beginning on March 1, 2027.